

Medicines - HCP - Article



[Dermatology](#)

Cosentyx® (secukinumab)

[Prescribing information](#)



Rheumatology

Cosentyx® (secukinumab)

[Prescribing information](#)



[Haematology](#)

FABHALTA®▼ (iptacopan)

[Prescribing information](#)



Haematology

JAKAVI® (ruxolitinib)

[Prescribing information](#)



Oncology

KISQALI® (ribociclib)

[Prescribing information](#)



Cardio-metabolic

LEQVIO®▼ (inclisiran)

[Prescribing information](#)



Oncology

SANDOSTATIN® LAR® (octreotide acetate)

[Prescribing information](#)



Haematology

SCEMBLIX®▼ (asciminib)

[Prescribing information](#)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL: <https://www.pro.novartis.com/uk-en/medicines>